Overview: Smooth Muscle Antibody IFA Dilutions TestIntroduction: The Smooth Muscle Antibody IFA Dilutions Test quantifies ASMA to diagnose autoimmune hepatitis, causing liver inflammation. Following 2023 AASLD guidelines, it uses immunofluorescence for high specificity, supporting liver screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected autoimmune hepatitis.
Other Names: ASMA IFA Dilutions Assay, Anti-Smooth Muscle Antibody Titer Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: ASMA dilution testing began in the 1970s with autoimmune hepatitis research. Immunofluorescence methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Quantifies ASMA to diagnose autoimmune hepatitis, guides treatment, and evaluates patients with liver inflammation.
Test Parameters: 1. ASMA Presence 2. ASMA Titer
Pretest Condition: No fasting required. Collect serum or saliva. Report history of liver inflammation or autoimmune symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver inflammation, jaundice, or history of autoimmune hepatitis. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, autoimmune hepatitis implications, and risks of sample collection.
Procedural Considerations: Uses indirect immunofluorescence assay (IFA) with serial dilutions to quantify ASMA titers. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for autoimmune hepatitis diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: High ASMA titers confirm autoimmune hepatitis, guiding immunosuppressive therapy. Negative or low titers may require ANA or liver biopsy.
Specialist Consultation: Consult a hepatologist for result interpretation and treatment planning.
Additional Supporting Tests: ANA, liver function tests, or liver biopsy to confirm autoimmune hepatitis diagnosis.
Test Limitations: Non-specific for certain liver conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: AASLD Autoimmune Hepatitis Guidelines, 2023; Hepatology, Czaja AJ, 2022.
